View Future GrowthAbera Bioscience 과거 순이익 실적과거 기준 점검 0/6Abera Bioscience은 연평균 10.5%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 17%의 비율로 증가했습니다. 매출은 연평균 56.7%의 비율로 증가했습니다.핵심 정보10.47%순이익 성장률20.32%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률56.66%자기자본이익률-69.24%순이익률-137.46%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트공시 • Apr 13Abera Bioscience AB to Report Q1, 2026 Results on May 12, 2026Abera Bioscience AB announced that they will report Q1, 2026 results on May 12, 2026공시 • Jan 13Abera Bioscience AB to Report Fiscal Year 2025 Results on Feb 12, 2026Abera Bioscience AB announced that they will report fiscal year 2025 results on Feb 12, 2026공시 • Oct 15Abera Bioscience AB to Report Q3, 2025 Results on Nov 13, 2025Abera Bioscience AB announced that they will report Q3, 2025 results on Nov 13, 2025공시 • Jul 23Abera Bioscience AB to Report Q2, 2025 Results on Aug 21, 2025Abera Bioscience AB announced that they will report Q2, 2025 results on Aug 21, 2025공시 • Apr 14Abera Bioscience AB to Report Q1, 2025 Results on May 13, 2025Abera Bioscience AB announced that they will report Q1, 2025 results on May 13, 2025공시 • Jan 15Abera Bioscience AB to Report Fiscal Year 2024 Results on Feb 13, 2025Abera Bioscience AB announced that they will report fiscal year 2024 results on Feb 13, 2025모든 업데이트 보기Recent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Harry Rastedt was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 13Abera Bioscience AB to Report Q1, 2026 Results on May 12, 2026Abera Bioscience AB announced that they will report Q1, 2026 results on May 12, 2026공시 • Jan 13Abera Bioscience AB to Report Fiscal Year 2025 Results on Feb 12, 2026Abera Bioscience AB announced that they will report fiscal year 2025 results on Feb 12, 2026공시 • Oct 15Abera Bioscience AB to Report Q3, 2025 Results on Nov 13, 2025Abera Bioscience AB announced that they will report Q3, 2025 results on Nov 13, 2025공시 • Jul 23Abera Bioscience AB to Report Q2, 2025 Results on Aug 21, 2025Abera Bioscience AB announced that they will report Q2, 2025 results on Aug 21, 2025공시 • Apr 14Abera Bioscience AB to Report Q1, 2025 Results on May 13, 2025Abera Bioscience AB announced that they will report Q1, 2025 results on May 13, 2025공시 • Apr 10Orexo Announces Positive In-Vivo Proof-Of-Concept Data for Powder-Based Intranasal Vaccine Formulated with the Amorphox TechnologyOrexo AB (publ.) announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences ("Abera") entered in December 2024. The proof-of-concept study was conducted in rats where Abera's influenza vaccine candidate was administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology. Both formulations induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA). No difference in immune response was seen between the liquid nasal solution and the intranasal powder. An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic. Formulating vaccines in powder form using the AmorphOX technology provides the potential to develop cost-efficient, thermostable vaccines with no need for cold chain requirements.공시 • Jan 15Abera Bioscience AB to Report Fiscal Year 2024 Results on Feb 13, 2025Abera Bioscience AB announced that they will report fiscal year 2024 results on Feb 13, 2025공시 • Oct 15Abera Bioscience AB to Report Q3, 2024 Results on Nov 13, 2024Abera Bioscience AB announced that they will report Q3, 2024 results on Nov 13, 2024공시 • Jul 23Abera Bioscience AB to Report Q2, 2024 Results on Aug 21, 2024Abera Bioscience AB announced that they will report Q2, 2024 results on Aug 21, 2024공시 • Apr 16Abera Bioscience AB to Report Q1, 2024 Results on May 14, 2024Abera Bioscience AB announced that they will report Q1, 2024 results on May 14, 2024공시 • Jan 24Abera Bioscience AB to Report Fiscal Year 2023 Results on Feb 22, 2024Abera Bioscience AB announced that they will report fiscal year 2023 results on Feb 22, 2024공시 • Oct 16Abera Bioscience AB to Report Q3, 2023 Results on Nov 14, 2023Abera Bioscience AB announced that they will report Q3, 2023 results on Nov 14, 2023Board Change • Sep 20No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Aug 21No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Jul 18Abera Bioscience AB to Report Q2, 2023 Results on Aug 16, 2023Abera Bioscience AB announced that they will report Q2, 2023 results on Aug 16, 2023Board Change • Feb 23No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Feb 02No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Jan 25Abera Bioscience AB to Report Fiscal Year 2022 Results on Feb 23, 2023Abera Bioscience AB announced that they will report fiscal year 2022 results on Feb 23, 2023Board Change • Nov 21No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.공시 • May 17Abera Bioscience AB, Annual General Meeting, Jun 14, 2022Abera Bioscience AB, Annual General Meeting, Jun 14, 2022.Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역Abera Bioscience가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:8WK 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비31 Mar 2612-1628031 Dec 2512-1022030 Sep 2517-119030 Jun 2516-117031 Mar 2516-117031 Dec 2415-116030 Sep 2413-416030 Jun 249-817031 Mar 245-1318031 Dec 233-1719030 Sep 230-1919030 Jun 231-1920031 Mar 231-2021031 Dec 222-1921030 Sep 222-1720030 Jun 222-1517031 Mar 221-1112031 Dec 211-910030 Sep 211-89030 Jun 211-78031 Mar 210-66031 Dec 201-44030 Nov 201-34031 Dec 192-24031 Dec 182-35031 Dec 171-220양질의 수익: 8WK 은(는) 현재 수익성이 없습니다.이익 마진 증가: 8WK는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 8WK는 수익성이 없지만 지난 5년 동안 연평균 10.5%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 8WK의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 8WK은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(7.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 8WK는 현재 수익성이 없으므로 자본 수익률이 음수(-69.24%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/15 17:09종가2026/06/12 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Abera Bioscience AB는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Niklas ElmhammerCarlsquare ABHerman KuntscherCarlsquare AB
공시 • Apr 13Abera Bioscience AB to Report Q1, 2026 Results on May 12, 2026Abera Bioscience AB announced that they will report Q1, 2026 results on May 12, 2026
공시 • Jan 13Abera Bioscience AB to Report Fiscal Year 2025 Results on Feb 12, 2026Abera Bioscience AB announced that they will report fiscal year 2025 results on Feb 12, 2026
공시 • Oct 15Abera Bioscience AB to Report Q3, 2025 Results on Nov 13, 2025Abera Bioscience AB announced that they will report Q3, 2025 results on Nov 13, 2025
공시 • Jul 23Abera Bioscience AB to Report Q2, 2025 Results on Aug 21, 2025Abera Bioscience AB announced that they will report Q2, 2025 results on Aug 21, 2025
공시 • Apr 14Abera Bioscience AB to Report Q1, 2025 Results on May 13, 2025Abera Bioscience AB announced that they will report Q1, 2025 results on May 13, 2025
공시 • Jan 15Abera Bioscience AB to Report Fiscal Year 2024 Results on Feb 13, 2025Abera Bioscience AB announced that they will report fiscal year 2024 results on Feb 13, 2025
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Harry Rastedt was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 13Abera Bioscience AB to Report Q1, 2026 Results on May 12, 2026Abera Bioscience AB announced that they will report Q1, 2026 results on May 12, 2026
공시 • Jan 13Abera Bioscience AB to Report Fiscal Year 2025 Results on Feb 12, 2026Abera Bioscience AB announced that they will report fiscal year 2025 results on Feb 12, 2026
공시 • Oct 15Abera Bioscience AB to Report Q3, 2025 Results on Nov 13, 2025Abera Bioscience AB announced that they will report Q3, 2025 results on Nov 13, 2025
공시 • Jul 23Abera Bioscience AB to Report Q2, 2025 Results on Aug 21, 2025Abera Bioscience AB announced that they will report Q2, 2025 results on Aug 21, 2025
공시 • Apr 14Abera Bioscience AB to Report Q1, 2025 Results on May 13, 2025Abera Bioscience AB announced that they will report Q1, 2025 results on May 13, 2025
공시 • Apr 10Orexo Announces Positive In-Vivo Proof-Of-Concept Data for Powder-Based Intranasal Vaccine Formulated with the Amorphox TechnologyOrexo AB (publ.) announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences ("Abera") entered in December 2024. The proof-of-concept study was conducted in rats where Abera's influenza vaccine candidate was administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology. Both formulations induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA). No difference in immune response was seen between the liquid nasal solution and the intranasal powder. An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic. Formulating vaccines in powder form using the AmorphOX technology provides the potential to develop cost-efficient, thermostable vaccines with no need for cold chain requirements.
공시 • Jan 15Abera Bioscience AB to Report Fiscal Year 2024 Results on Feb 13, 2025Abera Bioscience AB announced that they will report fiscal year 2024 results on Feb 13, 2025
공시 • Oct 15Abera Bioscience AB to Report Q3, 2024 Results on Nov 13, 2024Abera Bioscience AB announced that they will report Q3, 2024 results on Nov 13, 2024
공시 • Jul 23Abera Bioscience AB to Report Q2, 2024 Results on Aug 21, 2024Abera Bioscience AB announced that they will report Q2, 2024 results on Aug 21, 2024
공시 • Apr 16Abera Bioscience AB to Report Q1, 2024 Results on May 14, 2024Abera Bioscience AB announced that they will report Q1, 2024 results on May 14, 2024
공시 • Jan 24Abera Bioscience AB to Report Fiscal Year 2023 Results on Feb 22, 2024Abera Bioscience AB announced that they will report fiscal year 2023 results on Feb 22, 2024
공시 • Oct 16Abera Bioscience AB to Report Q3, 2023 Results on Nov 14, 2023Abera Bioscience AB announced that they will report Q3, 2023 results on Nov 14, 2023
Board Change • Sep 20No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Aug 21No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Jul 18Abera Bioscience AB to Report Q2, 2023 Results on Aug 16, 2023Abera Bioscience AB announced that they will report Q2, 2023 results on Aug 16, 2023
Board Change • Feb 23No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Feb 02No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Jan 25Abera Bioscience AB to Report Fiscal Year 2022 Results on Feb 23, 2023Abera Bioscience AB announced that they will report fiscal year 2022 results on Feb 23, 2023
Board Change • Nov 21No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • May 17Abera Bioscience AB, Annual General Meeting, Jun 14, 2022Abera Bioscience AB, Annual General Meeting, Jun 14, 2022.
Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.